In April 2015, the US Agency for International Development (USAID) and Janssen Therapeutics officially launched the bedaquiline donation initiative. As part of this initiative, Janssen committed to providing bedaquiline at no cost to 30,000 patients with multidrug-resistant tuberculosis (MDR-TB) over a four-year period. Bedaquiline is the first anti-TB medicine to be approved by the U.S. Food … Read more
Archive Georgia
Bedaquiline Treatment Reaches 200 Patients in Georgia
Georgia is one of the first countries to benefit from the USAID‑Janssen Therapeutics bedaquiline (BDQ) donation program. Along with delamanid, BDQ is one of only two new TB medicines released to the market in over 40 years. These medicines are being used for the treatment of MDR-TB patients, as well as TB patients who have … Read more
Expanding options for TB patients in Georgia: An interview with Maya Kavtaradze
In April 2015, USAID and Janssen Therapeutics officially launched the bedaquiline (BDQ) donation initiative, under which Janssen committed to providing free BDQ to 30,000 patients with multidrug-resistant tuberculosis (MDR-TB) over a four-year period. Along with delamanid, BDQ is one of only two new TB medicines released to the market in over 40 years. These medicines … Read more
Georgia: Establishing a drug safety management and monitoring system for bedaquiline and other drugs
In April 2015, USAID and Janssen Therapeutics officially launched the bedaquiline donation initiative, under which Janssen committed to providing free bedaquiline to 30,000 patients with multidrug-resistant tuberculosis (MDR-TB) over a four-year period. Bedaquiline is the first anti-TB medicine to be approved by the U.S. Food and Drug Administration in more than 40 years, and is … Read more
Drug safety and monitoring are key as bedaquiline donation program launches in Georgia
In April 2015, USAID and Janssen Therapeutics officially launched the bedaquiline donation initiative, under which Janssen committed to providing free bedaquiline to 30,000 patients with multidrug-resistant tuberculosis (MDR-TB) over a four-year period. Bedaquiline is the first anti-TB medicine to be approved by the U.S. Food and Drug Administration in more than 40 years, and is … Read more
